DMK
ARRY

David M. Knott’s Array Biopharma Inc ARRY Stock Holding History

David M. Knott’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,900
Closed -$85K – 115
2017
Q3 		$85K Sell
6,900
-21,500
-76% -$200K 0.04% 87
2017
Q2 		$238K Buy
28,400
+16,400
+137% +$134K 0.1% 67
2017
Q1 		$107K Buy
+12,000
New +$128K 0.05% 57

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

David M. Knott's ARRY Position: Q4 2017 in Review

David M. Knott sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 6,900 shares — an estimated $85K sold.

David M. Knott first reported a position in ARRY in Q1 2017 and held it in 3 quarters. The position peaked at $238K in Q2 2017. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

  • David M. Knott reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
  • David M. Knott sold 6,900 Array Biopharma Inc shares in Q4 2017, an estimated $85K.
  • David M. Knott first reported a position in Array Biopharma Inc in Q1 2017 and held it in 3 quarters.
  • David M. Knott's Array Biopharma Inc position peaked at $238K in Q2 2017.
  • 191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on David M. Knott's 13F filing for Q4 2017, filed 13 Feb 2018.